The Changing Specialty Drug Reimbursement Landscape
Advancements in medicine have led to the development of new specialty drugs treating a greater number of rare conditions. In the early 1990s,... In DRG Blog, Market Access/ June, 2019 Are patients the victims of value assessments in the age of ICER?
Drug Prices Scrutinized As the existential challenges become starker for health care in the United States, scrutiny over the price of drugs is... In DRG Blog, Market Access/ April, 2019 The Future of Rheumatology
Topics of discussion at the annual ACR/ARHP in October 2018 The annual meeting of the American College of Rheumatology/American Rheumatology Health... In DRG Blog, Market Access/ December, 2018 Will the Institute for Clinical and Economic Review Evolve as a formal HTA body in the US?
Growing role of ICER in the value-driven healthcare system The U.S. healthcare system is unique in many ways, with one key differentiator being the... In DRG Blog, Market Access/ November, 2018 Taiwan and Innovative Contracting – A Look at What's Ahead
Global healthcare systems are noticing a shift towards value-based healthcare with an increased focus on managing rising expenses. Innovative... In DRG Blog, Market Access/ October, 2018 All Aboard the Cigna Express: It’s Going to be Quite the Ride
With the Department of Justice giving its official sign-off, Cigna’s $52 billion purchase of Express Scripts, which is the last remaining large... In DRG Blog, Market Access/ September, 2018 How Disney is Disrupting Orlando Healthcare
American employers experimenting with direct provider contracts usually do it on a small scale, but Walt Disney World Resorts in Orlando is fully... In DRG Blog, Market Access/ September, 2018 Swedish Elections 2018: Political Uncertainty Has the Industry Watching Closely
With an uncertain election result looming, the life sciences industry may soon see challenges to Sweden’s traditionally smooth political climate. On... In DRG Blog, Market Access/ September, 2018 How are Medical Device Companies Responding to Value-Based Healthcare?
Medical devices are an integral part of the healthcare ecosystem, and any changes to the functioning of this system can have a direct and significant... In DRG Blog, Market Access/ August, 2018 How Pfizer’s Decision to Halt Price Impacts the Healthcare Industry
President Donald Trump has made no secret his disapproval of unreasonable price increases implemented by pharma companies. The feud between pharma and... In DRG Blog, Market Access/ August, 2018 Can Amazon’s Move to Acquire Pillpack Disrupt Healthcare?
Amazon has finally entered the market by taking a small share of the $560 billion U.S. prescription drug industry. Pillpack, a small online drug... In DRG Blog, Market Access/ July, 2018 Judge Blocks Kentucky Medicaid Work Requirement
In a blow to the administrations of President Donald Trump and Gov. Matt Bevin, a federal judge blocked Kentucky’s Medicaid work requirement on June... In DRG Blog, Market Access/ July, 2018 Which Factors will Influence Payers’ Reimbursement of Bipolar Drugs?
Key finding: There is a lack of consensus among payers regarding which select factors most drive their reimbursement decisions for emerging bipolar... In DRG Blog, Market Access/ June, 2018 A Sustainable U.S. Biosimilars Market Requires Sustainable Pricing
A Sustainable U.S. Biosimilars Market Requires Sustainable Pricing: Insights from the World Biosimilars Congress USA Recently, I had the opportunity... In DRG Blog, Market Access/ June, 2018 States Continue to Embrace Obamacare Despite Trump’s Opposition
Virginia’s passage of Medicaid expansion in late May 2018 is further proof that states will continue to embrace key tenets of Obamacare despite the... In DRG Blog, Market Access/ June, 2018 Which Factors Will Drive Preferred Reimbursement of SLE Therapies for U.S. Payers?
Key finding: Head-to-head trial data demonstrating a drug is at least as efficacious as Benlysta – the only targeted therapy approved for systemic... In DRG Blog, Market Access/ May, 2018 Global Market Access: 2017 Key Events and Future Impacts
This live session took place on Tuesday, April 17th 2018. Led by expert analysts from Decision Resource Group’s Global Market Access Insights team,... In downloads/ April, 2018 Cleanup on Aisle 6: Seven possible results of a Walmart–Humana deal
When The Wall Street Journal first broke the news that retail titan Walmart is talking with Humana about possible acquisition, it seemed a bit far-... In DRG Blog, Market Access/ April, 2018 International Reference Pricing & Brexit: 4 Thought-Provoking Insights
For IRP, the impact did not wait. International reference pricing (IRP) is defined as the practice of using the price(s) of a medicine in one or... In DRG Blog, Market Access/ April, 2018 What Walmart-Humana Would Mean for Healthcare
In December 2017, CVS Health announced plans to purchase Aetna for $69 billion, followed by speculation that a Walmart-Humana deal would be next... In DRG Blog, Market Access/ April, 2018